GnRH_A用药方案及其在控制性超促排卵中的应用进展被引量：3

下载PDF

导出

摘要促性腺激素释放激素拮抗剂(GnRHA)自20世纪90年代末开始应用于临床体外受精,但仍存在很多悬而未决的问题。目前尚无理想的拮抗剂用药方案,灵活用药方案似乎要科学合理一些。GnRHA无起爆效应,促排时间短,促性腺激素用量少,使用方便、经济,可有效预防卵巢过度刺激综合征的发生。但可能会导致妊娠率和胚胎种植率降低。对于低反应者是否用拮抗剂方案取代激动剂短周期方案还存在争议。理论上拮抗剂周期应适时添加黄体生成激素,但实践中研究结果不一,是否添加黄体生成激素还无定论。

作者朱亮邢福祺

机构地区南方医科大学南方医院生殖医学中心

出处《国外医学（计划生育．生殖健康分册）》 2007年第4期183-186,共4页

关键词促性腺激素释放激素拮抗剂控制性超促排卵辅助生殖技术

分类号 R714.8 [医药卫生—妇产科学]

引文网络
相关文献

参考文献19

1The ganirelix dose-finding study group. A double-blind, randomized, dose-finding study to assess the efficacy of the gonadotrophin- releasing hormone antagonist ganirelix (Org 37462) to prevent premature luteinizing hormone surges in women undergoing ovarian stimulation with recombinant follicle stimulating hormone (Puregon)[J]. Hum Repred, 1998, 13(11): 3023-3031.
2Mochtar MH, Dutch Ganirelix Study Group. The effect of an individualized GnRH antagonist protocol in folliculogensis in IVF/ICSI [J]. Hum Reprod, 2004, 19(8): 1713-1718.
3Ludwig M, Katalinic A, Diedrich K. Use of GnRH antagonists in ovarian stimulation for assisted reproductive technologies compared to the long protocol[J]. Arch Gynecol Obstet, 2001, 265(4): 175-182.
4Al-Inany H, Aboulghar M. GnRH antagonist in assisted reproduction: a Cochrane review[J]. Hum Reprod, 2002, 17(4): 874-875.
5Roulier R, Chabert-Orsini V, Sitri MC, et al. Depot GnRH agonist versus the single dose GnRH antagonist regimen (cetrorelix, 3mg) in patients undergoing assisted reproduction treatment [J]. Reprod Biomed Online, 2003, 7(2): 185-189.
6Berger BM, Ezcurra D, Appler MM. Gonadotropin releasing hormone (GnRH) antagonist (cetrolelix) versus GnRH agonist treatment-an age and gonadotropin matched study in young normal responders [J ]. Fertil Steril, 2004, 82[ Suppl 2]: S235-S236.
7Larry IB, Samuel JC, Bradley SH, et al. A randomized prospective trial comparing gonadotropin-releasing hormone (GnRH) antagonist/recombinant follicle-stimulating hormone (rFSH) versus GnRH- agonist/rFSH in women pretreated with oral contracepives before in vitro fertilization[J]. Fertil Steril, 2005, 83(2): 321-330.
8de Jong D, Macklon NS, Eijkemans MJ, et al. Dynamics of the development of multiple follicles during ovarian stimulation for in vitro fertilization using recombinant follicle-stimulating hormone (puregon) and various doses of the gonadotropin-releasing hormone antagonist ganirelix (Orgalutran/Antagon) [J]. Fertil Steril, 2001, 75(4): 688-693.
9Shamma F, Grossman P, Abuzeid M, et al. Comparison of daily ganirelix administration to a long protocol agonist for controlled ovarian hyperstimulation in oocyte donors: the results of a prospective randomized controlled trial [J]. Fertil Steril, 2003, 80 [Suppl 3 ]: S37.
10Prapas N, Prapas Y, Panagiotidis Y, et al. GnRH agonist versus GnRH antagonist in oocyte donation cycles: a prospective randomized study[J]. Hum Reprod, 2005, 20(6): 1516-1520.

同被引文献34

1张四友,郑敏.促性腺激素释放激素激动剂替代绒毛膜促性腺激素诱导排卵预防卵巢过度剌激综合征的初步观察[J].生殖医学杂志,2004,13(5):273-275. 被引量：12
2Xavier P,Gamboa C,Calejo L.A randomised study of GnRH antagonist (cetrorelix) versus agonist (busereline) for controlled ovarian stimulation:effect on safety and efficacy.Eur J Obstet Gynecol Reprod Biol,2005,120(1):185-189.
3Albano C,Felberbaum RE,Smitzl J,et al.Ovarian stimulation with HMG:results of a prospective randomized phase Ⅲ European study comparing the luteinizing hormone-releasing hormone (LHRH)-antagonist cetrorelix and the LHRH-agonist buserelin.Hum Reprod,2000,15(3):2421-2425.
4The North American Ganirelix Study Group:M Fluker,W Schoolcraft,R T Scott,et al.Efficacy and safety of ganirelix acetate versus leuprolide acetate in womenundergoing controlled ovarian hyperstimulation.Fertil Steril,2001,75(1):38-45.
5Roulier R,Chabert-Orsini V,Sitri MC,et al.Depot GnRH agonist versus the single dose GnRH antagonist regimen (cetrorelix,3mg)in patients undergoing assisted reproduction treatment.Repred Bioned Online,2003,7(2):185-189.
6Ye H,Huang GN,Zeng PH,et al.IVF/ICSI outcomes between cycles with luteal estradiol (E2) pre-treatment before GnRH antagonist protocol and standard long GnRH agonist protocol:a prospective and randomized study.J Assist Reprod Genet,2009,26:105-111.
7Juni P,Altman DG,Egger M.Assessing the quality of controlled clinical trials.BMJ,2001,323:42-46.
8Stroup DF,Berlin JA,Morton SC,et al.Meta-analysis of observa-tional studies epidemiology:a proposal for reporting.JAMA,2000,283(15):2008-2012.
9European and Middle East Orgalutran Study Group.Comparable clinical outcome using the GnRH antagonist ganirelix or a long protocol of the GnRH agonist triptorelin for the prevention of premature LH surges in women undergoing ovarian stimulation.Hum Reprod,2001,16(4):644-651.
10Olivennes F,Belaisch-Allart J,Emperaire JC.Prospective,randomized controlled study of in vitro fertilization-embryo transfer witha single dose of a luteinizing hormone releasing hormone (LHRH) antagonist(cetrorelix) or a depot formula of anLH-RH agonist (triptorelin).Fertil Steril,2000,73(2):314-320.